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Abstract
Background: Angiogenesis plays a role in the progression of osteosarcoma, as well as in other mesenchymal
tumors and carcinomas, and it is most commonly assessed by vascular endothelial growth factor (VEGF) expression
or tumor CD31-positive microvessel density (MVD). Tumor VEGF expression is predictive of poor prognosis, and
chemotherapy can affect the selection of angiogenic pattern. The aim of the study was to investigate the clinical
and prognostic significance of VEGF and CD31 in osteosarcoma, both at diagnosis and after neoadjuvant
chemotherapy, in order to identify a potential role of chemotherapy in angiogenic phenotype.
Methods: A retrospective analysis was performed on 16 patients with high grade osteosarcoma. In each case
archival pre-treatment biopsy tissue and post-chemotherapy tumor specimens were immunohistochemically
stained against CD31 and VEGF, as markers of angiogenic proliferation both in newly diagnosed primary
osteosarcoma and after multidrug chemotherapy including high-dose methotrexate (HDMTX). The correlation
between clinicopathological parameters and the degree of tumor VEGF and CD31 expression was statistically
assessed using the c
2 test verified with Yates’ test for comparison of two groups. Significance was set at p < 0,05.
Results: Expression of VEGF was positive in 11 cases/16 of cases at diagnosis. Moreover, 8 cases/16 untreated
osteosarcomas were CD31-negative, but the other 8 showed an high expression of CD31. VEGF expression in
viable tumor cells after neoadjuvant chemotherapy was observed in all cases; in particular, there was an increased
VEGF expression (post-chemotherapy VEGF - biopsy VEGF) in 11 cases/16. CD31 expression increased in 11 cases/16
and decreased in 3 cases after chemotherapy. The data relating to the change in staining following chemotherapy
appear statistically significant for VEGF expression (p < 0,05), but not for CD31 (p > 0,05).
Conclusions: Even if the study included few patients, these results confirm that VEGF and CD31 expression is
affected by multidrug chemotherapy including HDMTX. The expression of angiogenic factors that increase
microvessel density (MVD) can contribute to the penetration of chemotherapeutic drugs into the tumor in the
adjuvant stage of treatment. So VEGF could have a paradoxical effect: it is associated with a poor outcome but it
could be a potential target for anti-angiogenic therapy.
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Osteosarcoma is the most common malignant bone
tumor in adolescents and young adults [1-3]. Because it
is a systemic disease it requires a combined treatment
consisting of neoadjuvant chemotherapy, wide tumor
excision, adjuvant chemotherapy and, if necessary, resec-
tion of metastases. Multimodality treatments have mark-
edly improved the prognosis for patients with
osteosarcoma [4,5] and life expectancy is now 10 years
for 50-70% of patients [2]. Despite these therapeutic
advances and the identification of several prognostic fac-
tors [6], pulmonary metastasis occurs in approximately
40-50% of osteosarcoma patients; it is the most frequent
cause of death [4,7-11], and there are no effective risk
stratification categories. Because it is particularly impor-
tant to predict the probability of a recurrence of the
tumor at an early stage and to customize treatment pro-
tocols [7], the possibility of identifying new biological
parameters associated with more aggressive tumor beha-
vior and with a poor prognosis could be very useful.
Recent studies have focused on the role of angiogenesis
in osteosarcoma, albeit with controversial results
[8,12,13]. Angiogenesis is known to be a fundamental
factor in the local growth of tumors and in progression
with metastases, and is most commonly assessed by
measuring either the expression of vascular endothelial
growth factor (VEGF) in cancer cells or tumor CD31-
or CD34-positive microvessel density (MVD). Cancer
cells respond to an early hypoxic stage by activating sig-
naling pathways that induce cell proliferation, the pro-
duction of angiogenic factors such as VEGF and new
endothelial cell formation in order to provide a new vas-
cular supply [14,15].
VEGF is a dimeric glycoprotein that is a highly speci-
fic mitogen for vascular endothelial cells in vitro, as well
as inducing migration and preventing apoptosis of these
cells in vivo; VEGF expression by tumor cells is stimu-
lated by hypoxia, paracrine cytokines and activated
oncogenes and it provides a wide surface of permeable
CD31-positive microvessels from which tumor cells can
be sustained and enter the circulation [4,14,16,17].
VEGF expression in primary tumors and metastases
shows a statistically significant correlation with poor
prognosis in several patholo g i e ss u c ha sb r e a s t ,l u n g ,
renal, gastric, colon-rectal and esophageal carcinomas
[18-20]. A correlation between the histological grade of
malignancy and VEGF expression has recently been
found also in chondrosarcoma[21,22].
Several studies have evaluated the potential role of
angiogenesis, and of VEGF in particular, also in osteo-
sarcoma; however the majority of these included hetero-
geneous series and produced conflicting results because
VEGF expression in osteosarcoma was evaluated only
before or only after neoadjuvant chemotherapy, in pri-
mary tumors and/or in metastases. Nevertheless, these
studies demonstrated that VEGF has a predictive signifi-
cance as a marker of poor prognosis and of the risk of
metastasis [4,7,17,23-25]. Recently the prognostic role of
post-chemotherapy VEGF expression as well as the
changes in VEGF expression following chemotherapy
have been evaluated [26,27]: multidrug chemotherapy
appeared to reduce VEGF expression by viable tumor
cells, even though the series analyzed were not homoge-
neous in terms of staging or grading and the che-
motherapy protocols did not include methotrexate. The
rate of necrosis in resected tumor specimens, of more
or less than 90% in respectively “good” or “poor”
responders to neoadjuvant chemotherapy [3] still
remains the more important prognostic factor [1]; how-
ever, if chemotherapy can affect tumor angiogenesis, dif-
ferent expression levels of VEGF in osteosarcoma before
and after chemotherapy could be considered an addi-
tional biologic factor predictive of potential distant
metastasis and/or local relapse and a marker of chemo-
sensitivity. The effects of multidrug chemotherapy
including high-dose methotrexate (HDMTX) on tumor
angiogenesis and VEGF expression are in any case still
unknown.
The aim of this study was to investigate the clinical
and prognostic significance of VEGF in osteosarcoma
and its correlation with CD31-positive microvessel den-
sity (MVD), in order to identify a potential role of che-
motherapy in an angiogenic phenotype. The Authors
report the immunohistochemical results of VEGF
expression in 16 cases of osteosarcoma both at diagnosis
and after neoadjuvant chemotherapy including HDMTX.
Methods
A retrospective analysis was performed on 16 patients
with high grade osteosarcoma, treated in the Units of
Orthopedic Surgery and Clinical Oncology of the Catho-
lic University from 2000 to 2006. For each patient, the
clinicopathological characteristics included: age at diag-
nosis, sex, histological subtype, site, surgical technique,
local relapse, metastasis, disease-free and overall
survival.
After a detailed history and examination, all patients
were subjected to instrumental investigations which
included: plain radiographs and CT scan of the affected
bone; MRI of the entire affected extremity; plain radio-
graphs and CT scan of the chest to screen patients for
metastatic disease. All patients were finally staged
according to the Enneking staging system [28]; all
received the same treatment consisting of radical tumor
excision and multiagent neoadjuvant and adjuvant
chemotherapy.
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apy (high dose methotrexate 12000 mg/m
2/dose, cispla-
tin 45 mg/m
2/dose, adriamycin 75 mg/m
2/dose),
according to the Scandinavian osteosarcoma protocol,
SSG XIV [10]. Adequate margins were achieved in all
cases at the time of surgery.
Four archival tissue blocks were selected from core
tumor tissue in each patient; of these, 2 were taken
f r o mt h ed i a g n o s t i cb i o p s ya n d2f r o mt h er e s e c t e d
tumor after neoadjuvant chemotherapy; only viable sec-
tions of baseline and resected tumor were evaluated for
this study. Samples were immunohistochemically stained
for CD31 expression as a specific marker of tumor
MVD and for VEGF expression as being indicative of
angiogenic proliferation; 5 nm thick serial sections were
retrieved from the formalin-fixed paraffin-embedded tis-
sue blocks, deparaffinized in xylene and rehydrated
through graded alcohols. Antigen retrieval was per-
formed by microwave heating with 1 mM EDTA (pH
9.0) buffer solution for 12 minutes. Sections were trea-
ted with 1% hydrogen peroxide in methanol to block
endogenous peroxidase activity. After a brief wash in
PBS, 2 sections from each patient (respectively pre and
post-treatment) were incubated with purified mouse
antihuman CD31 monoclonal antibody at 1:100 dilution
(Novocastra); immunolocalization of VEGF was per-
formed using a rabbit polyclonal IgG antibody at 1:100
dilution (Santa Cruz Biotechnologies). Antibody binding
was detected with a biotinylated conjugated peroxidase
antibody at 1:200 dilution (Vector-Biolab). Immunohis-
tochemical reaction was indirectly amplified using the
avidin-biotin-peroxidase complex technique (Vector-Bio-
lab). The specific antibody binding was visualized using
3,3’-diaminobenzidine tetrahydrochloride (DAB, Vector-
Biolab). The degree of tumor angiogenesis in terms of
microvessel density (MVD) was determined by assessing
CD31 as a specific endothelial cell marker. The number
of CD31-positive vessels was counted in four randomly
selected areas of a 1 mm
2 high power field (HPF), and
the average was calculated. As a parameter of total sur-
face area of vasculature, the total perimeter of vessels
was measured in four randomly selected areas of a 0,25
mm
2 field using an image analyzer (Carl Zeiss Axiovi-
sion 3.1, Germany); MVD was defined as low (< 10 ves-
sels/HPF), moderate (10-40 vessels/HPF) or high (> 40
vessels/HPF). Assessment of VEGF expression was
based on the overall intensity of membranous and cyto-
plasmic staining within the tumor cells and the number
of stained cells/HPF. Four grades were assigned: nega-
tive-low (-: < 25 cells/HPF); moderate (+: 25-50 cells/
HPF); strong (++: 50-75 cells/HPF) and very strong
(+++: > 75 cells/HPF). Negative controls were included
by omitting VEGF antibody during the primary antibody
incubation, and human thyroid tissue was taken as
positive control. Counterstaining was performed with
Harris haematoxylin and sections were examined under
the light microscope (Carl Zeiss Axioskop 40, Germany)
by a single pathologist blinded to the patients’ clinical
characteristics. No section from resected tumors had
100% post-chemotherapy necrosis, which was evaluated
following criteria reported by Picci [3].
Statistics
Descriptive statistics were calculated. The relationship
between clinicopathological parameters and levels of
post-chemotherapy tumor VEGF expression was statisti-
cally assessed using the c
2 test verified with Yates’ test
for the comparison of two groups. The relationship
between the change in VEGF expression after che-
motherapy and disease-free survival and overall survival
was analyzed using Kaplan-Meier survival curves. Signif-
icance was set at p < 0,05. Disease-free survival was
evaluated considering the interval between diagnosis and
relapse or last follow-up.
Results
Table 1 summarizes the clinical parameters of 16
patients with high grade osteosarcoma of the extremities
treated between 2000 and 2006. The mean age was
17,25 years (range, 13-40 years). Twelve patients were
male and 4 were female. At the time of diagnosis, no
patient had evidence of metastatic disease. Thirteen
tumors were located in the distal femur, 1 in the proxi-
mal tibia and 2 in the proximal humerus. The distribu-
tion of patients according to the Enneking staging
system showed stage IIA in 15 cases (93,75%), and stage
IIB in 1 patient (6,95%). All cases were histologically
classified as central high grade osteosarcoma, except 1
Table 1 Patients and clinical characteristics
Patients 16
Male/Female 12/4
Average age
(range)
17.25
(13-40)
Histotype: Central high grade 15
Dedifferentiated parosteal 1
Site: Distal femur 13
Proximal tibia 1
Proximal humerus 2
Resection: Extra-articular 1
Intra-articular 15
Reinsertion: Direct 12
TREVIRA tube 4
Relapse 5
Metastasis 7
Death 5
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grade osteosarcoma.
All patients underwent neoadjuvant multiagent che-
motherapy including high dose methotrexate [10,29],
adriamycin and cisplatin (HDMTX-ADM-CDP) followed
by wide surgical resection; limb-sparing procedures
included intra-articular (15 cases) and extra-articular (1
case) resection and reconstruction with modular pros-
thesis (MUTARS, Implantcast®).
After evaluation of the degree of necrosis (> or < 90%
tumor cells) in the resected tumor specimens following
criteria reported by Picci [3], all patients received adju-
vant chemotherapy according to current protocols
[10,29] and their classification as “good” or “poor”
responders: patients classified as good responders were
treated for 21 weeks with cycles of ADM, MTX, and
CDP, while poor responders received a longer treatment
that also included ifosfamide or etoposide, with no
severe toxicity-related complications.
Clinical, MRI and chest-XR follow-up was performed
every 3 months in the first 2 years, then each six
months; the mean follow-up period was 72 months
(range, 36-108 months). During the follow-up, 7 patients
were affected by lung metastases (43,75%), and 5 also
developed local relapse (31,25%). In all cases, relapse
was treated with limb amputation. At the time of the
latest review (May, 2009) 5 patients (31,25%) affected by
both lung metastases and local relapse had died of their
disease (Table 1).
For all 16 primary osteosarcomas, both biopsy and
resection specimens were immunohistologically
stained using antibodies specific to VEGF and CD31,
in order to investigate the clinical significance of
angiogenesis in osteosarcoma and the effects of che-
motherapy including HDMTX in neo-vascularization
(Figures 1, 2).
VEGF staining on biopsy specimens was defined as
positive in 11 out of 16 cases (68,75%) (Figure 3): 6 of
these (54,5%) showed moderate (+) VEGF staining,
while the remaining 5 (45,5%) were strongly (++)
VEGF-positive. CD31 was expressed on biopsy speci-
mens in only 50% of cases (Figure 3). At the time of
diagnosis VEGF expression was thus more common
than CD31 expression. Immunohistochemistry on
post-chemotherapy tumor resection specimens showed
the expression of VEGF in all 16 treated osteosarco-
mas, albeit with different degrees of staining in viable
tumor cells, and of CD31 in microvessels, even in spe-
cimens that were VEGF and/or CD31-negative at
b i o p s y( F i g u r e4 ) .T h e r ew a sac h a n g ei nV E G Fa n d
CD31 expression following neoadjuvant chemotherapy:
in particular, there was an increased VEGF expression
in 11 cases/16 and no reduction in VEGF expression
was observed after chemotherapy in any case (Figure
5); however, CD31 expression increased in 11 cases/16
and decreased in 3 cases after chemotherapy (Figure
6); in 9 out of 11 cases with over-expression of VEGF
(post-chemotherapy VEGF - biopsy VEGF), an
increased CD31 staining was also found (Figures 5, 6).
The data relating to the change in staining following
chemotherapy appear statistically significant for VEGF
over-expression (p < 0,05), but not for CD31 (p >
0,05). No association was found between post-che-
motherapy VEGF expression and patient gender or age
(Table 2), but a correlation with anatomical localiza-
tion was observed (p < 0,05). Furthermore, a statisti-
cally significant association was found between VEGF
over-expression in treated osteosarcomas and local
relapse, lung metastasis and survival (Table 2). The
highest VEGF-positive (++, +++) osteosarcomas at
biopsy with increased VEGF expression after treatment
were the most clinically aggressive tumors; they devel-
oped local relapse and/or lung metastases earlier and
led to the death of patients (p < 0,05). Kaplan-Meier
survival curves (Figure 7A, B) showed a poorer prog-
nosis for patients who had an increased VEGF expres-
sion after chemotherapy than for those whose post-
treatment VEGF expression was unchanged.
Figure 1 VEGF expression in osteosarcoma before and after chemotherapy. Pre-chemotherapy biopsy (×200) and post-chemotherapy
resection specimens (×600) showing immunostaining for VEGF.
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Osteosarcoma is a systemic disease and hematogenous
spreading is therefore essential for its local proliferation
and dissemination to distant parts of the anatomy [1].
It is well-known that angiogenesis is an early stage in
the growth of carcinomas and mesenchymal tumors:
VEGF expression correlates with stage, grade and prog-
nosis of patients with gastro-enteric, lung and breast
carcinomas, soft-tissue sarcomas and chondrosarcomas
[12,18-20,22].
Several studies have examined the clinical significance
of angiogenesis-related biomarkers (VEGF, CD31, CD34,
etc.) in osteosarcoma, but their results are at times in
conflict and few reports relate to studies with large
series.
According to Kaya [4] VEGF-positive immunostaining
in untreated tumor specimens was predictive of lung
metastases and of short overall and disease-free survival.
This finding was also assessed by Charity [17] in a retro-
spective study on resected stage IIB osteosarcomas
around the knee: VEGF expression in more than 25% of
tumor cells after neoadjuvant chemotherapy correlated
with shorter overall and disease-free survival. In con-
trast, in a larger series analyzed by Kreuter [8], the mea-
surement of high levels of CD31-positive microvessel
density in pretreatment tumor samples was a favorable
Figure 2 CD31 expression in osteosarcoma before and after chemotherapy.P r e - c h e m o t h e r a p yb i o p s y( × 4 00) and post-chemotherapy
resection specimens (×600) showing immunostaining for CD31.
Figure 3 Bar charts showing levels of VEGF and CD31 expression in pre-chemotherapy biopsy specimens.
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Figure 5 Changes in VEGF expression after neoadjuvant chemotherapy are compared for each patient.
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response to chemotherapy.
Ek [13] evaluated the expression of VEGF and CD31/
34 as markers of MVD in pre-treatment biopsy and
found that all were expressed moderately or strongly in
almost all specimens, showing that osteosarcoma is
marked by moderate-to-high tumor microvessel density.
However, there was no statistical correlation between
VEGF expression, MVD, clinicopathological features and
disease outcomes.
A recent immunohistochemical study focused on
hypoxia-inducible factor (HIF-1a) and VEGF expression
as markers of hypoxia in specimens from primary and
metastatic sites: a higher level of VEGF and HIF-1a
expression was observed in pulmonary metastases,
showing a potential correlation with prognosis and
response to chemotherapy. No correlation between
VEGF, micro-vascular density and clinical outcomes was
found in this study either [14]. None of these studies
considered the possible role of chemotherapy in the
selection of angiogenic patterns in osteosarcoma.
VEGF and aV integrin expression were compared for
the first time in untreated osteosarcomas with different
Enneking stages and in the same patients after che-
motherapy (ADM-CDP-IFO) by Huang [26], confirming
VEGF expression in osteosarcoma before treatment.
Interestingly, the strong VEGF and aV integrin staining
were significantly reduced after chemotherapy; however,
residual strong staining of VEGF but not of aV integrin
Figure 6 Changes in CD31 expression after neoadjuvant chemotherapy are compared for each patient.
Table 2 Correlation between unchanged (↔) and
increased (↑) post-chemotherapy VEGF expression and
clinicopathological parameters; statistics significance
p < 0,05 with 1 grade of freedom.
VEGF immunostaining after CHT
Parameters VEGF ↔ VEGF ↑ p
Age
≥ 17 1 7
<1 7 4 4 p = 0.11
Sex
Male 4 8
Female 1 3 p = 0.11
Site
Femur 2 11
Other bones 3 0 p = 0.02
Relapse
Present 0 5
Absent 5 6 p = 0.04
Metastases
Present 1 6
Absent 4 5 p = 0.04
Survival
Dead 0 5
Alive 5 6 p = 0.04
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ing stages and a higher incidence of local relapse and
distant metastases. This study did not take into account
t h er o l eo fH D M T X - i n c l u s i v ec h e m o t h e r a p yi n
osteosarcoma.
Bajpai [27] analyzed both baseline and post-che-
motherapy VEGF expression in a series of 31 patients
affected by osteosarcoma, finding 90% agreement
between a positive baseline VEGF expression and a
higher histological grade; moreover, the decrease in
VEGF expression in the viable cells following che-
motherapy showed a significant association with favour-
able histological necrosis. Thus, high VEGF expression
in tumor cells surviving in post-chemotherapy resected
osteosarcomas is an important negative prognostic fac-
tor, because it is related to poor chemosensitivity. How-
ever, this series included patients with a
disproportionate stage distribution, both metastatic and
non-metastatic at diagnosis, and treated with only three
cycles of cisplatin and doxorubicin.
In the present series, VEGF expression was evaluated
through immunohistochemical analysis both at diagnos-
tic biopsy and in the resected tumor specimens of 16
patients affected by non-metastatic high grade osteosar-
coma of the extremities, in order to define a potential
effect of neoadjuvant chemotherapy with HDMTX on
tumor angiogenesis. Interestingly, patients included in
this study belonged to a homogeneous series in terms of
grade of malignancy and Enneking staging (IIA in 15
cases/16); the only patient affected by a parosteal osteo-
sarcoma (stage IIB) had the same prognosis as the other
patients because of the histological dedifferentiation in
central high grade osteosarcoma [28]. Moreover, the
Authors attempted to identify a correlation between the
change in angiogenic pattern following chemotherapy,
t h et e n d e n c yt ol o c a lr e l a p s ea n d / o rm e t a s t a s e sa n d
survival.
In accordance with the literature the study demon-
strates that a moderate-high microvessel density (MVD)
is a typical aspect of osteosarcoma at the time of pre-
sentation, as shown by the moderate-to-strong VEGF
and CD31 expression found respectively in about 70%
and 50% of biopsy specimens. VEGF expression is
higher than CD31 at biopsy, suggesting that VEGF is a
more objective and sensitive marker of angiogenic regu-
lation; it can therefore be used to evaluate the prognos-
tic role of angiogenesis in osteosarcoma, as well as in
other carcinomas and mesenchymal tumors
[12,18,19,22,25,26]. The comparison of VEGF and CD31
expression in biopsy and resection specimens suggests
the possibility that neoadjuvant chemotherapy might
influence angiogenesis in osteosarcoma. Preoperative
chemotherapy including HDMTX seems to increase
angiogenesis in high grade osteosarcoma, because VEGF
and CD31 are over-expressed (post-chemotherapy VEGF
- biopsy VEGF) in the majority of resected tumor speci-
mens. Tumor necrosis and/or chemo-induced hypoxia
could promote the up-regulation of VEGF by viable
tumor cells and then the proliferation of CD31-positive
endothelial cells. There was an increase in VEGF and
CD31 expression after multidrug chemotherapy includ-
ing HDMTX, but this was statistically significant only
Figure 7 Kaplan-Meier survival curve in relation to post-chemotherapy VEGF expression in viable tumor cells.D i s e a s e - f r e e( A)a n d
overall (B) survival of patients affected by osteosarcoma. Y-axis = Survival proportion; X-axis = follow up in months; group 1 = post-
chemotherapy increased VEGF expression; group 2 = post-chemotherapy unchanged VEGF expression.
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were included in the series. Epidemiologic parameters
such as patients’ gender and age were not significantly
associated with VEGF over-expression after chemother-
apy; on the contrary, a correlation with femoral localiza-
tion was found (p < 0,05), mainly due to the
disproportionate distribution of cases, as 13 cases out of
16 were localized in the femur. In the present series, 5
patients out of 16 (31,25%) developed both local relapse
and pulmonary metastases and subsequently died. Inter-
estingly, the increase of VEGF expression after preo-
perative chemotherapy in these patients positively
correlated with relapse of osteosarcoma, lung metastases
and survival (p < 0,05).
The Authors assume that different results between
this study and Hoang’ [26] or Bapjai’s [27] reports could
be related to different multidrug protocols (MTX vs
ifosfamide), but they cannot conclude that MTX is the
primary cause of that. Further study should be per-
formed in order to conclude about it.
Angiogenesis in osteosarcoma can be considered as a
diagnostic marker of tumor progression, in terms of
local growth and metastatic potential: in this series, the
change in VEGF following chemotherapy correlates with
a poorer prognosis. Furthermore, increased VEGF
expression by viable tumor cells in resected tumors
should be considered as a prognostic marker of a more
aggressive phenotype after neoadjuvant chemotherapy,
because chemo-resistant tumor cells are potentially
responsible for local relapse and/or metastases. Together
with low (< 90%) tumor necrosis [1,3], the increase in
VEGF expression after neoadjuvant chemotherapy could
be an additional biological marker predictive of a poor
response to treatment and poor prognosis. On the other
hand, as a consequence of the increase in angiogenic
factors, high microvessel density (MVD) could facilitate
the spreading of chemotherapeutic drugs in the adjuvant
stage of treatment.
The effects of anti-angiogenic therapy in the treatment
of osteosarcoma have been investigated in mouse tumor
models [5,15], but not yet in clinical trials. However,
Tsunemi [5] and Kaya [30] found concomitant tumor
resistance both in animal models and in 10 patients
with osteosarcoma: the removal of the primary tumor
significantly promotes the early development of distant
metastases through the activation of systemic angiogen-
esis. Thus, patients with osteosarcoma in whom serum
levels of VEGF are post-operatively elevated could be
good candidates for adjuvant anti-angiogenic therapy in
order to prevent progression of distant metastases.
In conclusion, VEGF could have a role as a marker
predictive of poor prognosis after neoadjuvant che-
motherapy, but also as a specific target for post-opera-
tive anti-angiogenic therapy. Thus, anti-angiogenic
therapy could augment the effects of adjuvant che-
motherapy through the inhibition of VEGF, especially in
elderly patients, in spinal or pelvic sites that are difficult
to treat with wide surgery [6], and most of all, in “poor
responders” to neoadjuvant chemotherapy, who are
usually affected by the highest VEGF-positive
osteosarcomas.
Conclusions
Although multidrug chemotherapy and wide surgery
have markedly improved the prognosis of osteosarcoma,
it is necessary to find some new molecular targets and
therapeutic solutions in order to deal with pulmonary
metastases and local relapse, which are still a real chal-
lenge in the treatment of this tumor. Several studies
have focused on the role of angiogenesis in osteosar-
coma and research is being directed towards anti-angio-
genetic factors in order to reduce its metastatic
potential. In this study chemotherapy-induced VEGF
expression in resected tumor specimens is shown to be
a negative prognostic factor correlated with local and
systemic progression; nevertheless, VEGF expression
after neoadjuvant chemotherapy should be considered a
specific target for adjuvant anti-angiogenic therapy.
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